ArticleRSC advances2026
A composite lateral flow test substrate by capillary deposition of cellulose on synthetic paper.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lateral flow test (LFT) has been a very popular platform for point-of-care testing (POCT). Traditionally, LFT uses (nitro)cellulose or microstructured polymer as the substrate. In this work, we develop a new LFT substrate by capillary deposition of cellulose on a microstructured polymer substrate off-stoichiometry thiol-ene (OSTE) synthetic paper, which is formed by interlocked slanted OSTE micropillars. This substrate has uniform thickness and stable lateral flow rate with customized design. The lateral flow rate can be adjusted by changing the dimensions of the LFT test strip, the concentration of deposited cellulose, or the Tween 20 concentration in cellulose to meet specific requirements. Spotting tests are conducted on this substrate to facilitate the following immobilization of immuno reagents. We successfully use this substrate in various applications including urine glucose detection (an enzyme-based immunoassay), iodate detection of saline solutions, and plasma separation from whole blood, which proves this substrate has enormous potential for LFT in POCT.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.